BIOMARIN PHARMACEUTICAL INC — Director's Dealing 2020

Jul 22, 2020

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: BIOMARIN PHARMACEUTICAL INC (BMRN)
CIK: 0001048477
Period of Report: 2020-07-20

Reporting Person: FUCHS HENRY J (President, Worldwide R&D)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2020-07-20	Common Stock	M	1250	$67.81	Acquired	104245	Direct
2020-07-20	Common Stock	M	75716	$67.81	Acquired	179961	Direct
2020-07-20	Common Stock	M	49423	$63.10	Acquired	229384	Direct
2020-07-20	Common Stock	S	126389	$130	Disposed	102995	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2020-07-20	Stock Option (Right to buy Common Stock)	$67.810	M	1250	Disposed	2023-05-14	Common Stock (1250)	Direct
2020-07-20	Stock Option (Right to buy Common Stock)	$67.81	M	75716	Disposed	2023-05-14	Common Stock (75716)	Direct
2020-07-20	Stock Option (Right to buy Common Stock)	$63.10	M	49423	Disposed	2024-06-03	Common Stock (49423)	Direct

Footnotes

F1: Trade made pursuant to a 10b5-1 plan executed on March 11, 2020.

F2: The price in column 4 is the weighted average price. The price actually received ranged from $130.00 to $130.04. The reporting person shall provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price.

F3: Reflects the number of options outstanding after the transactions from this specific stock option grant.